WW International

WW

Market cap $192M

The collaboration brings clinical and behavioural weight management together, offering UK members a more integrated path to sustainable weight loss.

WW International (NASDAQ:WW) on Thursday said its Weight Watchers platform is now available through Eli Lilly Co.'s (NYSE:LLY) LillyDirect digital health care platform, expanding access to branded GLP-1 weight-loss medications alongside clinical and behavioral support services.

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) and its affiliated medical groups (“Weight Watchers”), the global leader in science-backed weight management, is now accessible via Eli Lilly and Company's digital healthcare platform, LillyDirect®. This news further reflects Weight Watchers' continued focus on expanding access to trusted, brand-name GLP-1 medications paired with comprehensive clinical and behavioral support, designed for real life.

NEW YORK--(BUSINESS WIRE)--Galloway Capital Partners, LLC (“Galloway”), together with its affiliates, today announced that it has accumulated an ownership stake of approximately 8.42% in WW International, Inc. (“WW” or the “Company”). Galloway believes WW is materially undervalued despite owning one of the world's most recognized wellness brands and operating in the rapidly growing markets of weight management, metabolic health, GLP-1 support, and longevity. Following its recent restructuring,.

WW International, Inc. (WW) Q1 2026 Earnings Call Transcript

WW International NASDAQ: WW, operator of WeightWatchers, reaffirmed its 2026 financial outlook after reporting first-quarter results that reflected continued pressure in its legacy behavioral subscription business, offset in part by growth in its clinical weight-management offering and higher-value membership tiers.

WW International posted lower revenue in the first quarter, as behavioral subscription sales fell.

Total End of Period Subscribers of 2.7 million; End of Period Clinical Subscribers of 197 thousand, up 46% year-over-year Revenue of $168 million; Clinical Subscription Revenue of $39 million, up 32% year-over-year Reaffirms Full Year 2026 Financial Guidance Announces Fully Subscribed Debt Prepayment Solicitation as Part of Actions Expected to Reduce Debt by $42 Million NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced its results for the first quarter of fiscal 2026 ended March 31, 20261 in this Earnings Press Release and a Shareholder Letter issued today and posted on the Company's Corporate Website . “We remain confident in our strategy to build the industry-leading weight health platform.

The addition of Ozempic® pill will give Weight Watchers Med+ members a new FDA-approved oral GLP-1 option for adults living with type 2 diabetes The addition of Ozempic® pill will give Weight Watchers Med+ members a new FDA-approved oral GLP-1 option for adults living with type 2 diabetes

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced that it intends to utilize up to $40 million in cash to prepay and reduce the principal amount of its outstanding term loan.